

Research Article

PHARMACOKINETIC AND BIOEQUIVALENCE COMPARISON BETWEEN LUMEFANTRINE TABLETS 480MG: AN OPEN LABEL, BALANCED, RANDOMIZED-SEQUENCE, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY IN HEALTHY MALE VOLUNTEERS

Mahesh K^a, Nagasudheer Balusu^a, Manoj Kumar M^a, Swetha Savakula^a, Madhusudhan K^a, S.Sai Satyanaraya Reddy^b, Ravindra Reddy.S^b

^a ClinSync clinical Research Pvt Ltd, Hyderabad, Telangana, India.

^b Vardhaman College of Engineering, Hyderabad, Telangana, India.

Date Received: 12th August 2016; Date accepted: 29th August 2016; Date Published: 13th September 2016

E-mail: kadapakonda@gmail.com

Abstract

Background: This present bioequivalence study was designed to determine the pharmacokinetic, bioavailability and bioequivalence of Lumefantrine (480mg) tablets in comparison with COARTEMTM Lumefantrine (4x(120mg)) tablets after single dose administration under fasting conditions in healthy adult male subjects. Therefore the design of an open label, balanced, randomized, two-sequence, single dose, two way crossover study with a wash-


out period of at least 7 days was used. **Methods:** An open-labeled, balanced, single-dose with food, two-treatment, two-period, two-sequence, randomized crossover study was conducted in 18 healthy male volunteers. Each volunteer received a 480mg Lumefantrine tablets of the reference or test drug respectively. On the day of dosing, blood samples were collected before dosing and at various time points up to 216 hours after dosing. Analysis of Lumefantrine concentrations was performed using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method. The pharmacokinetic parameters including C_{max} , AUC_{0-t} , AUC_{0-inf} , T_{max} , $t_{1/2}$ and K_{el} were analyzed using the non-compartmental model. Drug safety and tolerability were assessed. **Results:** The pharmacokinetic parameters including C_{max} , AUC_{0-t} , AUC_{0-inf} , T_{max} , $t_{1/2}$ and K_{el} were analyzed using the non-compartmental model. Drug safety and tolerability were assessed. The primary pharmacokinetic parameters (C_{max} , AUC_{0-t} , AUC_{0-inf}) 90%CI were within the 80 to 125% interval required for bioequivalence as stipulated in the current regulations of the USFDA acceptance criteria. The geometric mean ratios (Test/Reference) between the two products of 480mg tablets under fasting condition 85.03% (82.56%-108.24%) for C_{max} ratios, 89.70%(85.46%-105.4%) for AUC_{0-t} ratios, 81.30% (80.12%-107.34%) for AUC_{0-inf} ratios of Lumefantrine, respectively. 18 volunteers had completed both treatment periods. There was no significant difference of the T_{max} parameter between the two formulations ($p > 0.05$). No serious adverse events related to the study drugs were found. **Conclusion:** This single dose study found that the test formulation of Lumefantrine (480mg) tablets are bioequivalent to the reference formulation COARTEMTM Lumefantrine (4x(120mg)) tablets in terms of extent and rate of absorption, under fasting condition in healthy adult male volunteers according to the USFDA regulatory guidance.

Keywords: Lumefantrine, Bioavailability, Bioequivalence, Intrasubject Variability

Introduction

Lumefantrine is an antimalarial, synthesized and developed by the academy of military medical sciences in Beijing, People's Republic of China[1-4].

This drug was registered in China in 1992 for the treatment of plasmodium falciparum malaria with combination of artemether, and has been subsequently further developed by Novartis Pharmaceuticals [5-8]. The combination of lumefantrine and artemether has proved very well tolerated and highly efficacious in children and adults [9-12], even against multi-drug resistant strains of Plasmodium falciparum [13-14]. The chemical name of Lumefantrine [15] is $[\pm]$ -2-dibutylamino-1-[2, 7-dichloro-9-[4-chlorobenzylidene]-9H-fluorene-4-yl] ethanol. It has the empirical formula $C_{30}H_{32}Cl_3NO$ with a molecular weight of 528.9 g/mol, and the following structural formula:



Lumefantrine is a yellow, crystalline powder that is freely soluble in N, N-dimethylformamide, chloroform, and ethyl acetate; soluble in dichloromethane; slightly soluble in ethanol and methanol; and insoluble in water. Lumefantrine is active against the erythrocytic stages of plasmodium falciparum [16-18]. Strains of *P. falciparum* with a moderate decrease in susceptibility to lumefantrine or artemether alone can be selected in vitro or in vivo. The exact mechanism by which lumefantrine, exerts its anti-malarial effect is not well defined. Available data suggest lumefantrine inhibits the formation of β -hematin by forming a complex with hemozoin. Both lumefantrine and artemether were shown to inhibit nucleic acid and protein synthesis. Absorption of lumefantrine, a highly lipophilic compound, starts after a lag-time of up to two hrs, with peak plasma concentrations about 6 to 8 hrs after administration. Lumefantrine is highly bound to human serum proteins in vitro [95.4% and 99.7%, respectively]. Lumefantrine is eliminated more slowly, with a terminal half-life of 3-6 days in healthy volunteers and in patients with falciparum malaria.

The rationale of this present bioequivalence study for two formulations of Lumefantrine tablets was

examined between generic drug Lumefantrine (480mg) tablets as the test product and COARTEM™ Lumefantrine (4x(120mg)) (NOVARTIS) as the reference product. This bioequivalence study could give assurance when prescribing less expensive generic drugs as alternatives with similar efficacy and safety.

The objective of this present study are to assess the single dose bioequivalence of Lumefantrine (480mg) tablets with COARTEM™ (NOVARTIS) in healthy, adult, human study participants under fasting conditions and to monitor the clinical status, adverse events, laboratory investigations and assess relative safety and tolerance Of Lumefantrine formulations under fasting conditions.

MATERIALS AND METHODS

According to the USFDA Regulatory individual product recommendations, two studies (Fasting and Fed) to be done with Lumefantrine (480mg) tablets to obtain marketing authorization in USA.

Study drugs

Lumefantrine (480mg) tablets and COARTEM™ from Novartis were used as the test and the reference products respectively. Both products were prepared as Lumefantrine tablets equivalent to Lumefantrine (480mg). Both the products were stored at controlled room temperature 25°C (77 °F).

Study population

The study protocol was approved by the Ethics Committee. In addition, the protocol was performed in accordance with the Declaration of Helsinki Principles [24] as outlined in the ICH-E6 Guidelines for Good Clinical Practice (GCP) [25]. All subjects were given a detailed description of the study and written informed consent was obtained prior to the enrollment.

The sample size was estimated based on, Coefficient of variation (C.V.) of the drug, sufficient statistical power to detect 20% difference with the power of 0.8 in C_{max} and AUC between the test and reference product, Regulatory requirements.

Sample size was based on estimates obtained from reported literature and previous studies. Assuming a formulation ratio (T/R) ranging from 0.95-1.05 a sample of 18 subjects including dropouts would be sufficient to show bioequivalence between the two

formulations with a power of at least 80%. Hence sample size of 18 subjects was enrolled in the study.

18 healthy male volunteers between the ages of 18-45 years with a body mass index between 18.5 kg/m² and 24.9 kg/m², with body weight equal to or not less than 50 kg were assessed to be in good physical condition by a complete medical screening including a medical history, physical examination and laboratory screening test for hematologic and blood biochemistry parameters. Subjects with a history of hypersensitivity to any ingredients in the Lumefantrine products and/or related drugs or its constituents or who were taking any medication or alcohol for a 21-day period prior to the study were excluded. Subjects who had a history of cardiovascular, hepatic, renal, gastrointestinal or hematologic disease were excluded from the study.

Study design

The study was an open-labeled, single-dose, study taken with out food, two-treatment, two-period, two-sequence randomized two way crossover with at least one week washout period. Subjects were randomly allocated to two groups by the sequence of product administered [Test-Reference (TR) and Reference-Test (RT) group]. In each period, 1x(480mg) tablet of Lumefantrine of the test or 4x(120mg) tablets of Lumefantrine of reference product was administered in the morning. Subjects were housed 12 hours prior to dosing in the clinical facility from a time adequate to ensure 10 hours supervised fasting before dosing and were allowed to leave the facility after 24.00 hours post-dose sample in each period. The subjects received a standard meal at about 4.0, 9.0 and 13.0 hours after dosing in each period. During housing, all meal plans were identical for all the periods. Drinking water was not allowed from one hour before dosing till one hour post-dose (except for 240 ± 02 mL of drinking water given for dosing). Before and after that, drinking water was allowed at *ad libitum*. After a minimum of 1 week washout period, the subjects were crossed over to the next treatment following the same procedure as conducted in the 1st period.

Sample collection

During dosing day in each period, 26 blood samples will be collected as per the following schedule:

Pre dose sample(0.00 hr) within 02 hrs prior to drug administration and the others at 0.25, 0.5, 0.75, 1.0, 1.25, 1.50, 1.75, 2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 14.0, 18.0, 20.0, 24.0, 48.0, 72.0, 96.0, 120.0, 144.0, 168.0, 192.0, 216.0 hr post dose. The total volume collected per study participant in this study will not exceed approximately 321 mL including up to 9 mL for screening, and 7-9 mL for post clinical assessment of lab parameters and 18 mL for discarded blood sample resulting from use of intravenous cannula for 12 hours and 2-9 mL was collected for repeat/additional lab tests, if required. For separating plasma, all blood samples were centrifuged at 3800 RPM for 10 minutes at 4°C ± 2°C. Centrifugation of all samples was done as early as possible after each sample draw time point. After centrifugation, plasma samples were aliquoted into two sets in properly labeled polypropylene tubes and immediately stored at about -60°C or colder.

Lumefantrine analysis by LC-MS/MS [26-27, 32-46]

The published LC-MS/MS methods [26-27] were validated according to USFDA regulations [28] for quantification of Lumefantrine from extracted subject plasma samples.

Pharmacokinetic and statistical analysis [29-31]

For the purpose of Average Bioequivalence analysis C_{max}, AUC_{0-t} and AUC_{0-inf} were considered as the primary variables and T_{max}, t_{1/2} and K_{el} were considered as the secondary variables. General Linear Model for analysis of variance (ANOVA) for crossover design was performed for log-transformed data and used to assess the effect of formulations, periods, sequences and subjects nested in sequence on these parameters. The difference between two related parameters was considered statistically significant for a *p*-value equal to or less than 0.05. 90% confidence interval (CI) for the ratios of geometric mean Test/Reference (T/R) for C_{max}, AUC_{0-t} and AUC_{0-inf} was calculated based on least squares means from the ANOVA of log-transformed data. The 90% geometric CI of the ratio (T/R) of least squares means from the ANOVA of the log-transformed C_{max}, AUC_{0-t} and AUC_{0-inf} should be within 80.00% to 125.00%.

Tolerability assessment

Physical examination and measurement of vital

signs (Blood Pressure, Pulse Rate and Oral Temperature) were examined at the time of Check-in, prior to administration of the each study drug (0.00 hr), 1.00, 3.00, 6.00, 12.00, 24.00, 48.0, 72.0, 96.0, 120.0, 144.0, 168.0, 192.0, 216.0hr post dose and

during the entire study period. Adverse events were monitored throughout the study and recorded by physicians.

Table 1: Demographic characteristics


Category		Treatment		TOTAL
		Test (T)	Reference (R)	
Age (years)	Mean $\pm$ SD	23.34 $\pm$ 4.10	23.84 $\pm$ 4.00	23.34 $\pm$ 4.05
	Range	18.0 – 36.0	19.0 – 36.0	18.0 – 36.0
	Median	23.0	23.0	23.0
	N	18	18	36
Age Groups	< 18	00	00	00
	18 – 40	12	12	24
	41 – 64	00	00	00
	65 – 75	00	00	00
	> 75	00	00	00
Gender	Female	00	00	00
	Male	18	18	36
Race	American	00	00	00
	Hispanic	00	00	00
	Caucasian	00	00	00
	Asian	18	18	36
Height (cm)	Mean $\pm$ SD	163.52 $\pm$ 5.69	164.24 $\pm$ 5.67	165.48 $\pm$ 5.67
	Range	157.0 – 174.0	159.0 – 177.0	157.0 – 177.0
	N	18	18	36
Weight (kg)	Mean $\pm$ SD	58.96 $\pm$ 6.24	61.56 $\pm$ 6.43	60.26 $\pm$ 6.41
	Range	52.0 – 70.0	52.0 – 77.0	52.0 – 77.0
	N	18	18	36
BMI (kg/m ²)	Mean $\pm$ SD	21.86 $\pm$ 1.46	22.10 $\pm$ 1.79	21.98 $\pm$ 1.62
	Range	20.1 – 24.8	20.0 – 24.9	20.0 – 24.9
	N	18	18	36

Table 2: Pharmacokinetic Parameters of and Lumefantrine Both Formulations

PK Parameters	Lumefantrine	
	Test	Reference
C _{max} [ng/mL]	2189.286	2574.865
AUC _{0-t} [ng.h/mL]	48432.99	53996.7
AUC _{0-inf} [ng.h/mL]	49428.29	60801.07
T _{max} [H]	5.042	5.833
K _{el} [H ⁻¹]	0.012	0.01
T _{1/2} [H]	72.403	73.475

Table 3: Bioequivalence Parameters for Lumefantrine

Parameter	Lumefantrine		
	C _{max}	AUC _t	AUC _{inf}
90% CI Lower Limit	82.56	85.46	80.12
90% CI Upper Limit	108.24	105.4	107.34
T/R Ratio (%)	85.03	89.70	81.30
Power	0.93	0.99	0.91
Intra Subject Variability	10.32	5.4	3.4
Inter Subject Variability	31.44	42.33	45.28
ANOVA (p-Value)			
Sequence	0.1	0.1	0.2
Period	0.8	0.6	0.1
Treatment	0.4	0.7	0.5

Fig 2: Time vs. Mean Plasma Concentration Graph of Lumefantrine

RESULTS

Study population

18 healthy male adults eligible for the study enrollment were randomly divided into 2 groups [Test-Reference (TR) and Reference-Test (RT)] according to the sequence of drug administration. All the subjects had completed both the periods. Thus, this study was balanced in each sequence and the results from 18 volunteers were used for pharma-

cokinetic and statistical analysis. Table 1 demonstrates the demographic characteristics of the volunteers.

Bioanalysis and pharmacokinetics [26-27, 32-46]

Chromatograms were acquired on a TSQ tandem mass spectrometry (Thermo Finnigan, Sanjose, CA, USA) equipped with Electrospray ionization (ESI) and connected to a PC runs with the standard

software Xcalibur 2.0.7 and LC Quan 2.5.6. Mass spectroscopic detection was performed on a Triple quadrupole instrument (Thermo, TSQ Quantum Discovery Max. The calibration curve was constructed by weighted $1/x^2$ least-square linear regression analysis of the peak area ratio (drug/ISTD) vs. the concentration of drug. The methods are sensitive enough in the range of 20 ng/ml to 3000 ng/ml for Lumefantrine.

Bioequivalence analysis

Ninety percent confidence interval of geometric mean ratios of bioavailability parameters between the test and reference formulation are presented in Table 3. The statistical analysis obtained from this study showed that the point estimate (90% CI) of the geometric mean ratio (GMR) (T/R) of C_{max} , AUC_{0-t} and AUC_{0-inf} was entirely within the equivalence criteria (80.00-125.00%) which was 85.03% (82.56%-108.24%) for C_{max} ratios, 89.70% (85.46%-105.4%) for AUC_{0-t} ratios, 81.30% (80.12%-107.34%) for AUC_{0-inf} ratios of Lumefantrine, respectively.

In addition, no significant difference of the T_{max} parameter between the two studied formulations was observed ($p > 0.05$). Therefore, it was concluded that the two formulations of Lumefantrine were bioequivalent in terms of rate and extent of absorption for the drug. The mean plasma concentration vs time profiles were given in Fig 2.

Tolerability

Almost all volunteers taking both formulations were noted for mild adverse events. Most common events were drowsiness, nausea and loss of appetite. However, no subject had any severe adverse event or withdrew from the study because of an adverse event.

DISCUSSION

An open-labeled, single-dose with out food, two-treatment, two-period, two-sequence randomized two way crossover design in 18 healthy adult volunteers was considered appropriate and standard for bioequivalence evaluation of the generic and the reference products. The study simulates real life conditions including the influence of meals as well as circadian effects on the performance of the product. For a safety reason, co-administration of the drug with food can reduce

nausea, a common side effect of Lumefantrine.

In general, the pharmacokinetic parameters for both formulations were similar to the pharmacokinetic parameters of Lumefantrine in previous published data. This study demonstrated that 90% CI of the logarithmic transformed of parameters C_{max} , AUC_{0-t} and AUC_{0-inf} were contained in 80.00-125.00%. In addition, no significant differences of the T_{max} values between the two formulations were observed ($p > 0.05$). Therefore, the two formulations of Lumefantrine are considered bioequivalent in terms of the rate and extent of absorption. Moreover, both formulations were well tolerated. Hence, the test and reference (COARTEM™) formulations of Lumefantrine (480mg) are bioequivalent.

CONCLUSION

This single dose study found that the test formulation Lumefantrine (480mg) tablets is bioequivalent to the reference formulation COARTEM™ Lumefantrine [4*120mg] tablets in terms of the extent and the rate of absorption, under fasting condition in healthy adult male volunteers according to the USFDA regulatory guidance.

REFERENCES

1. Laxminarayan R, Parry IWH, Smith DL, Klein E. should new antimalarial drugs be subsidized. J health econ. 29, 2010; 445-456.
2. World Health Organisation [2006], WHO guidelines for the treatment of malaria. 2nd edition, 1 may 2010.
3. World health Organisation [2009]. World Malaria Report, 1 may 2010.
4. Jared N. Cumming, Poonsakdi Ploypraditha and Gary H. Posnera. Antimalarial activity of artemisinin [qinghaosu] and related trioxanes, mechanism[s] of action. Advances in pharmacology. 37, 1996; 253-297.
5. Washington DC, Institute of medicine of the national academies saving lives, buying time. Economics of malaria drugs in an age of resistance. National Academies Press, 2004.
6. McCombie SC. Treatment seeking for malaria, a review of recent research. Soc Sci Med. 43, 1996; 933-945.
7. Williams HA, Jones CO. A critical review of behavioral issues related to malaria control in

- sub-Saharan Africa, Soc Sci Med. 59, 2004; 501-523.
8. Roll back malaria-2007[RBM], Affordable medicines facility-malaria [AMFm], 5 may 2010.
 9. Talisuna A, Grewal P, Rwakimari JB, Mukasa S, Jagoe G, et al. Cost is killing patients, Subsidising effective antimalarials. Lancet. 374, 2009; 1224-1226.
 10. Goodman C, Brieger W, Unwin A, Mills A, Meek S, et al. Medicine sellers and treatment in sub-Saharan Africa, Am J Trop Med Hyg. 77[6], 2007; 203-218.
 11. Smith LA, Jones C, Meek S, Webster J. Provider practice and user behavior interventions to improve prompt and effective treatment of malaria, do we know what works, Am j Trop Med Hyg, 80[3], 2009; 326-335.
 12. Oxfam. Challenging the myths about private healthcare in poor countries, Blind optimism. Oxfam briefing paper. 3 may 2010.
 13. C.Hatz, S.Abdulla, R.Mull, D.Schellenberg, I.Gathmann, P.kibatala, H.P.Beck, M.Tanner, C.Royce. Efficacy and safety of CGP 56697 [and benflumetol] compared with chlroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Tropical Medicine and Interantional Health. 3, 1998; 498.
 14. MV Vugt, P Wilairatana, B Gemperli, I Gathmann, L Phaipun, A Brockman, C Luxemburger, NJ White, F Nosten, and S Looareesuwan. Efficacy of six doses of -lumefantrine [benflumetol] in multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 60[6], 1999; 936-942.
 15. Janssen Pharmaceutica Products. Sporanox [Lumefantrine] injection. US Food and Drug Administration, 2002.
 16. Noor AM, Gething PM, Alegana VM, Patil A, Hay SI, et al. The risks of malaria infection in Kenya. BMC Infectious Diseases. 9, 2009; 180.
 17. Kangwana BB, Njogu J, Wasunna B, Kedenge SV, Memusi DN, et al. Malaria drug shortages in Kenya, a major failure to provide access to effective treatment. Am J Trop Med Hyg., 80, 2009; 737-738.
 18. Van Vugt M, Looareesuwan S, Wilairatana P, MC Gready R, Villegas L, Gathmann I, Mull R, Brockman A, White Nj, Nosten F. -lumefantrine for the treatment of multidrug-resistant falciparum malaria, Transactions of the Royal Society of Tropical Medicine and Hygeine. 94[5], Sep-Oct 2000; 545-8.
 19. Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, et al. Piloting the global subsidy, the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania Plos one, 4[9], 2009; 6857.
 20. Sabot O, Yeung S, Pagnoni F, Gordon M, Petty N, et al. Distribution of artemisinin-based combination therapies through private-sector channels, RFF Discussion Paper, 2009; 08-43.
 21. Dalessandro U, Talisuna M, Boelaert M, Should artemisinin-based combination treatment be used in the home-based manaalaria, Trop Med Int Health. 10, 2005; 1-2.
 22. Richard K. Haynes, Simone C. Vonwiller. Extraction of artemisinin and artemisinic acid, preparation of and new analogues, Transactions of the Royal Society of Tropical Medicine and Hygiene, 88[1], June 1994; 23-26.
 23. Dharmarajan Sriram, Vajja Sambasiva Rao, Kondapalli Venkata Gowri Chandrasekhar, Perumal Yogeewari. Progress in the research of artemisinin and its analogues as antimalarials. Natural Product Research, formerly natural product letters, 18[6], 2004; 503-527.
 24. World Medical Association Declaration Of Helsinki, Ethical Principles For Medical Research Involving Human Subjects, 59th WMA General Assembly, 2008
 25. International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use, Guideline For Good Clinical Practice, E6, 1996
 26. Raghunadha Reddy.S, Koteswara Rao.Divi, I.Sarath chandiran and K.N. Jayaveera. Quantification of in human plasma with liquid-liquid extraction by using fully validated high performance liquid Chromatography-Tandem mass spectrometric method, Journal of Pharmacy Research, August-2010, Voumel-3, Issue-8, Impact Factor-1.5, ISSN: 0974-6943.
 27. Raghunadha Reddy.S, M.P. Kalyan Reddy, Y.K.Naidu, Koteswara Rao.Divi, I.Sarath Chandiran and K.N. Jayaveera. Development and Validation of High Performance Liquid Chromatography-Tandem Mass Spectrometric Method for Quantification of Lumefantrine in

- Human Plasma with Precipitation, International Journal of Pharma Research and Development [IJPRD], Apr -2010, Volume-2, Issue-2, Page-1-9 and ISSN: 0974 – 9446.
28. U.S. Department of Health and Human Services Food and Drug Administration, Bioanalytical Method Validation, 2001.
 29. U.S. Department of Health and Human Services Food and Drug Administration, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations, 2003.
 30. U.S. Department of Health and Human Services Food and Drug Administration, Statistical Approaches to Establishing Bioequivalence, 2001.
 31. Raghunadha Reddy S, Koteswara Rao.Divi, I. Sarath Chandiran, K.N. Jayaveera, Y.K. Naidu, M.P. Kalyan Reddy. Development and validation of high-throughput liquid chromatography–tandem mass spectrometric method for simultaneous quantification of Clopidogrel and its metabolite in human plasma, Journal of Chromatography B, Elsevier Publications, February- 2010, volume-878, Issue:3-4, pages:502–508, Impact factor-2.977, ISSN: 1570-0232.
 32. Y.K.N, Raghunadha Reddy Seelam, Koteswara Rao Divi, Penchala Kalyan Reddy Mule, Sarath Chandiran I and Jayaveera K N. Simultaneous Quantification of Alverine And Its Metabolite P-Hydroxy Alverine In Human Plasma With Robotic Liquid-Liquid Extraction By Using Fully Validated LC-MS/MS and Its Application To A Bioequivalence Study, Journal Of Pharmacy Research, 2010, Volume-3, Issue-6, Page-1407-1411, Impact Factor-1.5, ISSN: 0974-6943.
 33. I.Sarath Chandiran, K. N. Jayaveera and Raghunadha Reddy. S., High-Throughput Liquid Chromatography–Tandem Mass Spectrometric Method for Simultaneous Quantification of Carvedilol and Its Metabolite 4-Hydroxyphenyl Carvedilol in Human Plasma and Its Application to Bioequivalence Study, Journal of Chemical and Pharmaceutical Research, , 2011, 3[2]:341-353, ISSN No: 0975-7384, CODEN[USA]: JCPRC5.
 34. I.Sarath Chandiran, K. N. Jayaveera and Raghunadha Reddy. S. Development and Validation of High-Throughput Liquid Chromatography–Tandem Mass Spectrometric Method for Quantification of Itraconazole and its Metabolite in Human Plasma. Scholars Research Library, Der Pharmacia Lettre, 2011, 3[2]: 316-328.
 35. I.Sarath Chandiran K.N. Jayaveera and Raghunadha Reddy.S, Pharmacokinetic and Bioequivalence Comparison Between Extended Release Capsules of Venlafaxine Hydrochloride 150mg: An Open Label, Balanced, Randomized-Sequence, Single-Dose, Two-Period Crossover Study In Healthy Indian Male Volunteers, International Research Journal Of Pharmacy [IRJP], 2[3], 2011,262-269, ISSN 2230-8407.
 36. Raghunadha Reddy. S, I. Sarath Chandiran, K. N. Jayaveera and Koteswara Rao. Divi. Quantification of Ursodeoxy Cholic acid in human plasma by using High performance liquid chromatography–tandem mass spectrometric method and its applications in pharmacokinetics, Journal of Chemical and Pharmaceutical Research, 2010, volume-2, issue-3, Pages:59-69 and ISSN No: 0975-7384.
 37. Raghunadha Reddy Seelam, Sarath Chandiran I, Koteswara Rao Divi, Jayaveera K. N., Development and Validation of High Performance Liquid Chromatography–Tandem Mass Spectrometric Method for Simultaneous Quantification of Telmisartan in Human Plasma, International journal of pharmaceutical sciences and Drug Research, 2010, Volume-2, Issue-3, Pages: 188-192 and ISSN No: 0975-248X.
 38. Raghunadha Reddy.S, I.Sarath chandiran, K.N. Jayaveera and Koteswara Rao.Divi. Quantification of ibuprofen in human plasma by using high throughput liquid chromatography–tandem mass spectrometric method and its applications in pharmacokinetics, scholars research library, archives of applied research, 2010, volume-2, issue-3, pages-101-111, ISSN-0975-508x,coden[USA] AASRC9.
 39. Raghunadha Reddy.S, Koteswara Rao.Divi, Y.K.Naidu, I.Sarath Chandiran, k.N. Jayaveera and M.P.Kalyan Reddy. Development and validation of high-performance liquid chromatography tandem mass spectrometric method for quantification of Clonidine in human plasma, journal of chemical and pharmaceutical sciences, April - June'2010, volume-3, issue-2.

40. Y.K.N, Raghunadha Reddy S., Koteswara Rao Divi, M.P. Kalyan Reddy, I. Sarath Chandiran and K.N. Jayaveera. Quantification of Levetiracetam in Human Plasma with Precipitation Extraction by Using Fully Validated LC-MS/MS and Its Application to a Bioequivalence Study, Research J. Pharm. and Tech., July-Sept 2010, Volume-3, Issue-3, and Page: 847-853 and ISSN: 0974-3618.
41. S.Raghunadha Reddy, Pobba Rajani, Koteswararao. Divi, YK Naidu, Sarath Chandiran I and MP Kalyan Reddy. Anti- inflammatory and analgesic activity of Smilax chinensis, Research Journal of Pharmaceutical, Biological and Chemical Sciences, April – June 2010, Volume-1, Issue-2, Pages: 1-8, ISSN: 0975-8585.
42. Kalyan Reddy MP, Jaya Chandra Reddy P, Raghunadha Reddy S, Jayaveera KN. Development and validation of bio-analytical method for Quantification of Pantoprazole in human plasma using LC-MS/MS, Journal of Pharmacy and Chemistry, July - September 2010, Volume-4, Issue-3, Pages:80-86 and ISSN No: 0973-9874.
43. Raghunadha Reddy S, Naidu YK, Koteswara Rao Divi, Ravikiran V, Sandhya Rani Y, Kalyan Reddy MP. Development and Validation of High Performance Liquid Chromatography Tandem Mass Spectrometric Method for Quantification of Aceclofenac in Human Plasma, Journal of Pharmacy and Chemistry, July - September 2010, Volume-4, Issue-3, Pages:89-95 and ISSN No: 0973-9874.
44. Mahitej Yadav Katteboina, Nageswara Rao Pilli, Ramesh Mullangi, Raghunadha Reddy Seelam and Shobha Rani Satla, LC-MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study, 10 November 2015, Biomed. Chromatogr.
45. I. Sarath Chandiran, Raghunadha Reddy Seelam, Seelam Sai Satyanaraya Reddy, Ravindra Reddy S, Bioequivalence and Pharmacokinetic Comparison between Extended Release Capsules of Carvedilol Phosphate 40mg: An Open Label, Balanced, Randomized- Sequence, Single-Dose, Two-Period Crossover Study in Healthy Male Volunteers, International Journal of Medicine and Pharmaceutical Research, 2015, 3(4): 1105–1114.
46. Raghunadha R Seelam, Sarath C Irisappan, Ravindra R Seelam, Sai SR Seelam, Bioequivalence comparison between two different Formulations of alverine citrate 120mg capsules: an open Label, balanced, randomized-sequence, single-dose, two period Crossover study in healthy male volunteers, Journal of Comprehensive Pharmacy, 2015, 2(3), 105-114.